0001127602-14-012774.txt : 20140326
0001127602-14-012774.hdr.sgml : 20140326
20140326174817
ACCESSION NUMBER: 0001127602-14-012774
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140324
FILED AS OF DATE: 20140326
DATE AS OF CHANGE: 20140326
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PERRIGO Co plc
CENTRAL INDEX KEY: 0001585364
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: TREASURY BUILDING
STREET 2: LOWER GRAND CANAL STREET
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: 269-673-8451
MAIL ADDRESS:
STREET 1: 515 EASTERN AVENUE
CITY: ALLEGAN
STATE: MI
ZIP: 49010
FORMER COMPANY:
FORMER CONFORMED NAME: PERRIGO Co Ltd
DATE OF NAME CHANGE: 20130828
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PAPA JOSEPH C
CENTRAL INDEX KEY: 0001242215
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36353
FILM NUMBER: 14719636
MAIL ADDRESS:
STREET 1: C/O WATSON PHARMACEUTICALS INC
STREET 2: 311 BONNIE CIRCLE
CITY: CORONA
STATE: CA
ZIP: 92880
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2014-03-24
0001585364
PERRIGO Co plc
PRGO
0001242215
PAPA JOSEPH C
C/O PERRIGO COMPANY
515 EASTERN AVENUE
ALLEGAN
MI
49010
1
1
1
President and CEO
Chairman
Ordinary Shares
2014-03-05
5
G
0
E
1155
0
D
95500
D
Ordinary Shares
2014-03-24
4
M
0
10000
58.85
A
105500
D
Ordinary Shares
2014-03-24
4
S
0
6045
157.0034
D
99455
D
Ordinary Shares
2014-03-24
4
S
0
1700
157.9071
D
97755
D
Ordinary Shares
2014-03-24
4
S
0
1000
159.0706
D
96755
D
Ordinary Shares
2014-03-24
4
S
0
1255
159.8121
D
95500
D
Employee Stock Option Right to Buy
58.82
2014-03-24
4
M
0
10000
0
D
2020-08-19
Ordinary Shares
10000
10183
D
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 11, 2013. This 10b5-1 sales plan will expire on the close of business November 11, 2014.
The price in column 4 is a weighted average. The prices actually received ranged from $156.58 to $157.56. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
The price in column 4 is a weighted average. The prices actually received ranged from $157.59 to $158.38. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
The price in column 4 is a weighted average. The prices actually received ranged from $158.74 to $159.59. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
The price in column 4 is a weighted average. The prices actually received ranged from $159.77 to $159.95. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
Grant has graded vesting schedule. Date Exercisable will vary for each vesting tranche.
/s/ Joseph C. Papa
2014-03-26